FREE WEBINAR

Optimizing Your Lab’s Precision Medicine Strategy
Through Rapid, Front-Line NGS



Join this webinar to explore the importance of rapid molecular testing and discover how first-line, targeted NGS can serve as a powerful tool for laboratories to streamline testing platforms and enhance lab efficiency.

Airing on April 16, 2025 at 1pm EST


60-Minute Webinar Sponsored By

Pillar_biosciences_logo_final_blue-green

Join Dr. Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology at Memorial Sloan Kettering Cancer Center (MSKCC), to explore the clinical need for rapid molecular testing, with a focus on leveraging first-line, targeted next-generation sequencing (NGS) to help laboratories consolidate their testing platforms and optimize workflows. Dr. Ewalt will discuss validation data and the concordance of Pillar Biosciences’ oncoReveal® Nexus (also branded by Memorial Sloan Kettering Cancer Center as MSK-REACT) with MSKCC's MSK-IMPACT panels. 

Key Topics:

  • The clinical need for a rapid molecular testing.  
  • Review how first-line, targeted NGS can be leveraged as a tool by laboratories to consolidate their testing platforms to optimize their laboratory.
  • Validation data and concordance of Pillar Biosciences’ oncoReveal® Nexus (branded by MSKCC as MSK-REACT) with MSKCC's MSK-IMPACT panels and how this type of rapid testing can be leveraged by other clinical laboratories as a tool to help sub-select and inform which patients should have.  
  • The clinical use and impact of this rapid NGS strategy at Memorial Sloan Kettering Cancer Center. 
Female scientists looking at a monitor in a laboratory

Expert Panel

Dr. Mark Ewalt, MD

Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology

Memorial Sloan Kettering Cancer Center (MSKCC)

Dr. Ewalt completed his medical school and residency training at Columbia University Medial Center followed by Hematopathology and Molecular Genetic Pathology fellowships at Stanford University.  For the past decade, he has been a practicing Hematopathologist and Molecular Pathologist in large academic institutions including Cedars-Sinai, the University of Colorado Anschutz Medical Campus, and Memorial Sloan Kettering Cancer Center.  His research interests including developing novel biomarkers for hematologic neoplasms and optimizing ultra-sensitive detection methods for measurable residual disease.  Prior to beginning his medical career, Mark worked as an analyst for Accenture LLP and had has brought those skills into optimizing clinical operations.

Who should attend?

  • Laboratory Directors
  • CEO, CFO
  • Molecular Pathologists
  • Oncologists

Hosted By

dark daily logo-no tags-FIT-white